2021
Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.
Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 146-146. DOI: 10.1200/jco.2020.39.28_suppl.146.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaRenal cell carcinomaStage IV renal cell carcinomaPalliative care utilizationNational Cancer DatabasePalliative careClinical factorsCare utilizationCell carcinomaStage IIITreatment-specific mannerStage III renal cell carcinomaPC utilizationMetastatic renal cell carcinomaPalliative care useDisease-specific symptomsMultivariable logistic regressionComprehensive cancer programsQuality of lifeOncological guidelinesSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusMultivariable analysis
2014
Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study
Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study. The World Journal Of Men's Health 2014, 32: 159-166. PMID: 25606565, PMCID: PMC4298819, DOI: 10.5534/wjmh.2014.32.3.159.Peer-Reviewed Original ResearchPrimary androgen deprivation therapyAndrogen deprivation therapyAdvanced prostate cancerProstate cancerDeprivation therapyDefinitive therapyMetastatic stageMedian pretreatment PSA levelBetter progression-free survivalProstate-specific antigen progressionPSA progression ratePretreatment PSA levelCharacteristics of patientsProgression-free survivalRetrospective multicenter studyMedian survival timeHigher clinical stageAndrogen blockadeMedical comorbiditiesPSA progressionPSA changePSA levelsClinical factorsMedian ageClinical efficacy